|

Trastuzumab deruxtecan (T-DXd) Clinical Trials

6 actively recruiting trials across 3 locations

Also known as: DS-8021a, ENHERTU, DS-8201a, ENHERTU®

Pipeline

Phase 2: 3Phase 1/2: 2

Top Sponsors

  • AstraZeneca2
  • MedSIR1
  • Gruppo Oncologico del Nord-Ovest1
  • GI Innovation, Inc.1
  • Daiichi Sankyo1

Indications

  • Cancer6
  • Breast Cancer3
  • Liver Disease1
  • HER2-positive Gastroesophageal Junction1
  • Colon Cancer Adenocarcinoma1

Other3 trials

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Phase 2
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Phase 2

Scottsdale, Arizona1 trial

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

La Jolla, California1 trial

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Site

Phase 1/2

Newark, Delaware1 trial

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.